Skip to main content

Table 1 Baseline characteristics and VAS pain scores according to the PNB sites

From: Efficacy of additional periprostatic apex nerve block on pain in each of 12 transrectal prostate core biopsies: a retrospective study

  Base Base and apex p
N 151 (49.7) 153 (50.3)  
Age (years) 67.86 ± 15.74 68.19 ± 8.59 0.740
PSA (ng/mL) 7.56 (5.40–11.59) 6.76 (4.47–10.19) 0.074
Prostate volume (mL) 36.55 ± 15.74 36.79 ± 16.78 0.900
History of prostate biopsy (n, %) 27 (17.9) 19 (12.4) 0.186
Positive DRE (n, %) 35 (35.7) 25 (28.4) 0.287
Prostate cancer detection rate (n, %) 95 (62.9) 95 (62.1) 0.882
Gleason score    0.171
6 (n, %) 18 (18.9) 26 (27.4)  
≥ 7 (n, %) 77 (81.1) 69 (72.6)  
Pain    
Probe insertion 3.39 ± 2.12 3.36 ± 2.43 0.905
PNB at base 2.91 ± 1.83 2.79 ± 1.94 0.591
PNB at apex   4.60 ± 2.50  
At 15 min post prostate biopsy 0.14 ± 0.58 0.16 ± 0.74 0.749
Time    
Periprostatic nerve block (min) 2.42 ± 0.77 2.59 ± 0.88 0.084
Prostate biopsy (min) 4.20 ± 2.59 4.66 ± 5.41 0.343
Adverse events    
Vasovagal syncope (n, %) 2 (1.3) 0 (0.0) 0.246
Allergic reaction (n, %) 0 (0.0) 0 (0.0)
AUR (n, %) 0 (0.0) 0 (0.0)
Urinary retention because of blood clot (n, %) 0 (0.0) 0 (0.0)
Fever (n, %) 0 (0.0) 0 (0.0)
  1. Data are expressed as number (%), mean ± standard deviation, and median (IQR range)
  2. AUR, acute urinary retention; DRE, digital rectal exam; IQR, interquartile; PNB, periprostatic nerve block; PSA, prostate specific antigen; VAS, visual analog scale